LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "idelalisib" as a keyword



Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia

Sign Up to like & get
recommendations! Published in 2018 at "Hematological Oncology"

DOI: 10.1002/hon.2480

Abstract: Light chain amyloidosis is characterized by the progressive deposition of immunoglobulin light chains into the extracellular tissue, leading to organ dysfunction. Usually, it is associated with an underlying clonal plasma cell dyscrasia and rarely with… read more here.

Keywords: idelalisib; lymphocytic leukaemia; light; amyloidosis ... See more keywords
Photo from wikipedia

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.

Sign Up to like & get
recommendations! Published in 2021 at "Acta pharmacologica Sinica"

DOI: 10.1038/s41401-021-00643-2

Abstract: Mantle cell lymphoma (MCL) is a lymphoproliferative disorder lacking reliable therapies. PI3K pathway contributes to the pathogenesis of MCL, serving as a potential target. However, idelalisib, an FDA-approved drug targeting PI3Kδ, has shown intrinsic resistance… read more here.

Keywords: mcl; idelalisib; inhibition; p300 cbp ... See more keywords

Inhibitory effect of Idelalisib on selenite-induced cataract in Sprague Dawley rat pups.

Sign Up to like & get
recommendations! Published in 2021 at "Current eye research"

DOI: 10.1080/02713683.2021.1988984

Abstract: PURPOSE The aim of this study was to evaluate the therapeutic effect of Idelalisib, Apelisib and Copanlisib on 8-day-old cataract SD rat pups. MATERIALS AND METHODS The rat model induced by sodium selenate (Na2SeO3) was… read more here.

Keywords: copanlisib; rat pups; idelalisib; group ... See more keywords

Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients

Sign Up to like & get
recommendations! Published in 2022 at "British Journal of Haematology"

DOI: 10.1111/bjh.18426

Abstract: Idelalisib, a reversible inhibitor of PI3Kδ (phosphoinositide‐3 kinase delta), showed remarkable activity in the phase II DELTA trial, leading to its approval by the European Medicines Agency (EMA) in patients with relapsed/refractory (R/R) follicular lymphoma… read more here.

Keywords: real life; idelalisib; follicular lymphoma; life ... See more keywords

A slowly developed severe cutaneous adverse reaction to idelalisib

Sign Up to like & get
recommendations! Published in 2018 at "Journal of the European Academy of Dermatology and Venereology"

DOI: 10.1111/jdv.14700

Abstract: Intracellular signal mediator phosphatidylinositol-3-kinase (PIK3K) –δ, an isoform of PIK3K, is expressed in hematopoietic cells especially in lymphoid lineage 1. Idelalisib is a novel PIK3K-δ targeted kinase inhibitor which is approved for relapsed follicular B-cell… read more here.

Keywords: adverse reaction; severe cutaneous; slowly developed; idelalisib ... See more keywords

Konsensusempfehlungen deutscher Experten - Management der Therapie mit Idelalisib

Sign Up to like & get
recommendations! Published in 2017 at "Oncology Research and Treatment"

DOI: 10.1159/000458426

Abstract: Idelalisib, die erste Substanz in der Wirkklasse der Phosphatidylinositol 3-Kinase delta (PI3Kδ)-Inhibitoren, ist in Deutschland für die Therapie von Patienten mit chronischer lymphatischer Leukämie (CLL) und follikulärem Lymphom (FL) zugelassen. Im Rahmen eines Expertenmeetings wurden… read more here.

Keywords: management; idelalisib; therapie mit; der ... See more keywords

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Sign Up to like & get
recommendations! Published in 2020 at "Blood"

DOI: 10.1182/blood-2020-133359

Abstract: Introduction: Patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) who are ineligible for intensive chemotherapy and autologous stem cell transplantation have limited therapeutic options and poor prognosis, and there is an unmet need for… read more here.

Keywords: treatment; research funding; idelalisib; cell ... See more keywords

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Sign Up to like & get
recommendations! Published in 2019 at "Health and Quality of Life Outcomes"

DOI: 10.1186/s12955-019-1232-8

Abstract: BackgroundIn a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients with relapsed/refractory chronic lymphocytic leukemia (R/R… read more here.

Keywords: bendamustine rituximab; placebo; idelalisib; quality life ... See more keywords

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells

Sign Up to like & get
recommendations! Published in 2017 at "Oncotarget"

DOI: 10.18632/oncotarget.14043

Abstract: Idelalisib, a PI3K inhibitor, specifically targeting p110δ, has been approved for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. However, the mechanisms of action of idelalisib in colon cancer cells are not… read more here.

Keywords: apoptosis; idelalisib; colon cancer; cancer cells ... See more keywords

Rapid and complete response to idelalisib in a case of Richter syndrome

Sign Up to like & get
recommendations! Published in 2019 at "OncoTargets and therapy"

DOI: 10.2147/ott.s187459

Abstract: Richter syndrome (RS) is an aggressive lymphoma arising on the back of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and is the most common B-cell malignancy in the Western world. In the majority of cases,… read more here.

Keywords: idelalisib; response; richter syndrome; complete response ... See more keywords

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

Sign Up to like & get
recommendations! Published in 2021 at "Frontiers in Immunology"

DOI: 10.3389/fimmu.2021.608625

Abstract: B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells.… read more here.

Keywords: selective inhibitor; idelalisib; cll patients; cell malignancy ... See more keywords